{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-083543","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2024-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.397907+00:00","generated_at":"2026-05-31T15:38:53.940815+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CVRx Q2 2024 revenue up 24% to $11.8M; net loss widens to $14.0M; updates FY guidance","bullets":["Q2 2024 revenue $11.8M (+24% YoY); U.S. HF revenue $10.5M (+27% YoY); net loss $14.0M ($0.65/share) vs $11.6M ($0.56) in Q2 2023.","Active implanting centers in U.S. reach 189, up 35% YoY; sales territories expanded to 42 from 39 in Q1.","Cash and equivalents $70.4M; net cash used in operating/investing $10.2M in Q2, down from $11.8M in Q1.","Hired Robert John as CRO, Dr. Philip Adamson as CMO, and other execs to strengthen commercial efforts.","FY 2024 guidance: revenue $50-53M; gross margin 83-85%; operating expenses $95-98M (narrowed from $92-98M); Q3 revenue $12.7-13.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-083543","json":"https://secwatch.observer/filing/0001104659-24-083543.json","markdown":"https://secwatch.observer/filing/0001104659-24-083543.md","text":"https://secwatch.observer/filing/0001104659-24-083543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465924083543/0001104659-24-083543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465924083543/tm2420331d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:38:53.940815+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}